Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies

Share Article

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has signed an exclusive licensing agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) technology platform. Under the licensing agreement, Catalent will continue development work on the platform, both internally and in conjunction with partner-sponsored programs.

This technology platform…can allow innovators to look to combinations earlier in clinical development, and could be the difference in a new treatment getting to patients

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has signed an exclusive licensing agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) technology platform. The platform has the potential to enable a consistent and cost-effective method to manufacture multiple recombinant antibodies or other recombinant proteins in a single batch culture. Under the licensing agreement, Catalent will continue development work on the platform, both internally and in conjunction with partner-sponsored programs. Catalent will also be able to leverage its own proprietary GPEx® technology to help enable that development.

“Combination antibody therapies are becoming the treatment standard for many indications within oncology, immuno-oncology, and infectious diseases,” commented Mike Riley, Vice President/General Manager, Catalent Biologics. He added, “This technology platform has the potential to allow production of multiple antibodies in a significantly more cost-effective manner. This can allow innovators to look to combinations earlier in clinical development, and could be the difference in a new treatment getting to patients.”

Excelimmune's antibody combination expression system is based on a key innovation: the use of stable pools of cells generated by multiple directed gene insertions, instead of clonal cell lines. This attribute contributes to a quick, stable, and flexible culture system for mixtures of cells producing different antibodies. This technology has the potential to pave the way for more consistent, cost-effective production of antibody combinations, which will allow complex antibody therapeutics to gain greater accessibility to the clinic.

About Catalent

Catalent, Inc. is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,600 people, including over 1,000 scientists, at 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling

Richard Kerns
Northern Exposure PR
+44 7974 579202
Email >
Visit website